Innovive, maker of mesothelioma drug, acquired by CytRx

"CytRx Corp. (CYTR), a biopharmaceutical company headquartered in Los Angeles, has completed its acquisition of Innovive Pharmaceuticals Inc. Innovive is the maker of a cancer vaccine that is currently being tested in mesothelioma, lung cancer, leukemia and myelodysplastic syndrome patients. The company also developed the cancer drug tamibarotene and other drug candidates targeting " (2008-10-1)
Read more...